Unveiling 4 Analyst Insights On Cencora
Portfolio Pulse from Benzinga Insights
Cencora (NYSE:COR) has been evaluated by 4 analysts over the last three months, showing a mix of bullish to bearish sentiments. Recent updates include raised price targets and ratings, with an average 12-month price target of $260.5, reflecting a 6.76% increase from the previous $244.00. Cencora, a leading pharmaceutical wholesaler, has shown impressive financial performance with significant revenue growth, high ROE, and ROA, despite a high debt-to-equity ratio.
May 02, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cencora has received mixed analyst ratings but shows a bullish trend with recent price target updates indicating a positive outlook. The company's strong financial performance and significant role in the pharmaceutical industry support potential stock growth.
The positive adjustment in analyst ratings and price targets, combined with Cencora's robust financial performance and strategic market position, suggest a likely appreciation in stock price in the short term. The company's significant revenue growth, high ROE, and ROA, despite a high debt-to-equity ratio, underline its operational efficiency and market dominance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100